Sionna Therapeutics is a pre-revenue biotechnology company with a concentrated pipeline focused on NBD1 stabilizers for cystic fibrosis, offering 25% analyst upside but scoring below the quality floor with a Piotroski score of 2/9, cash-burning operations, high short interest of 17%, and elevated put-to-call ratio of 2.0 that signal significant near-term risk.
Thesis pillars
- Cystic Fibrosis Pipeline Concentration↑Improving
- Pre Revenue Cash Burn Quality→Stable
- Analyst Upside Vs Elevated Short Interest↑Improving
- +1 more pillar — see the Why tab for full reasoning
Sionna Therapeutics, Inc. (SION) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $47.05: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizers to improve CFTR protein function in cystic fibrosis, targeting the F508del mutation present in ~90% of CF patients. The company reported net losses of $75.3 million in 2025, funded by... Read more
Sell if holding. Engine safety override at $47.05: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.1/10, moderate confidence.
Passes 4/8 gates (no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: speculative.
Recent developments
updated 2026-07-27Recent Developments — Sionna Therapeutics, Inc.
Latest news
- NEWS Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target — benzinga May 26, 2026 positive
- NEWS Stifel Maintains Buy on Sionna Therapeutics, Raises Price Target to $55 — benzinga May 18, 2026 positive
- NEWS BTIG Reiterates Buy on Sionna Therapeutics, Maintains $58 Price Target — benzinga May 13, 2026 positive
- NEWS Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- NEWS This UFP Industries Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday — benzinga May 5, 2026 positive
Generated 2026-07-27T14:48:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineNBD1 stabilizers10-K Item 1A: 'We are substantially dependent on the success of at least one of our nucleotide binding domain 1 ("NBD1") stabilizers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $47.05: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $43.65. Score 4.1/10, moderate confidence.
Take-profit target: $50.53 (-4.4% upside). Prior stop was $43.65. Stop-loss: $43.65.
Concentration risk — Pipeline: NBD1 stabilizers; Target reached (-4.4% upside); Quality below floor (1.6 < 4.0).
Sionna Therapeutics, Inc. trades at a P/E of N/A (forward -16.3). TrendMatrix value score: 4.0/10. Verdict: Sell.
17 analysts cover SION with a consensus score of 4.2/5. Average price target: $52.
What does Sionna Therapeutics, Inc. do?Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizers to improve CFTR protein...
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizers to improve CFTR protein function in cystic fibrosis, targeting the F508del mutation present in ~90% of CF patients. The company reported net losses of $75.3 million in 2025, funded by $310.3 million in cash and marketable securities after its February 2025 IPO, with no commercial revenue.